These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 17647245)

  • 41. Survival improvement in hormone-responsive young breast cancer patients with endocrine therapy.
    Yoon TI; Hwang UK; Kim ET; Lee S; Sohn G; Ko BS; Lee JW; Son BH; Kim S; Ahn SH; Kim HJ
    Breast Cancer Res Treat; 2017 Sep; 165(2):311-320. PubMed ID: 28601930
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Male breast cancer in the veterans affairs population: a comparative analysis.
    Nahleh ZA; Srikantiah R; Safa M; Jazieh AR; Muhleman A; Komrokji R
    Cancer; 2007 Apr; 109(8):1471-7. PubMed ID: 17342768
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A European, Observational Study of Endocrine Therapy Administration in Patients With an Initial Diagnosis of Hormone Receptor-Positive Advanced Breast Cancer.
    Bastiaannet E; Charman J; Johannesen TB; Schrodi S; Siesling S; van Eycken L; Walsh PM; Audisio RA; Boelens PG; Rubio IT; Jones N; Lewis J; van de Velde CJH
    Clin Breast Cancer; 2018 Aug; 18(4):e613-e619. PubMed ID: 29275865
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High-dose estrogen as salvage hormonal therapy for highly refractory metastatic breast cancer: a retrospective chart review.
    Mahtani RL; Stein A; Vogel CL
    Clin Ther; 2009; 31 Pt 2():2371-8. PubMed ID: 20110046
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Epidemiological characteristics, clinical outcomes and management patterns of metastatic breast cancer patients in routine clinical care settings of Greece: Results from the EMERGE multicenter retrospective chart review study.
    Kotsakis A; Ardavanis A; Koumakis G; Samantas E; Psyrri A; Papadimitriou C
    BMC Cancer; 2019 Jan; 19(1):88. PubMed ID: 30658600
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative effectiveness of everolimus-based therapy versus endocrine monotherapy among postmenopausal women with HR+/HER2- metastatic breast cancer: a retrospective chart review in community oncology practices in the US.
    Xie J; Hao Y; Li N; Lin PL; Ohashi E; Koo V; Signorovitch JE; Wu EQ; Yardley DA
    Curr Med Res Opin; 2015 Jun; 31(6):1095-103. PubMed ID: 25971725
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Patterns of relapse in breast cancer: changes over time.
    Yerushalmi R; Woods R; Kennecke H; Speers C; Knowling M; Gelmon K
    Breast Cancer Res Treat; 2010 Apr; 120(3):753-9. PubMed ID: 19701704
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial.
    Badwe R; Hawaldar R; Nair N; Kaushik R; Parmar V; Siddique S; Budrukkar A; Mittra I; Gupta S
    Lancet Oncol; 2015 Oct; 16(13):1380-8. PubMed ID: 26363985
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy.
    Park IH; Ro J; Lee KS; Kim EA; Kwon Y; Nam BH; Jung SY; Lee S; Kim SW; Kang HS
    J Clin Oncol; 2010 Jun; 28(16):2705-11. PubMed ID: 20421538
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Men and women show similar survival outcome in stage IV breast cancer.
    Wu SG; Zhang WW; Liao XL; Sun JY; Li FY; Su JJ; He ZY
    Breast; 2017 Aug; 34():115-121. PubMed ID: 28577471
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Survival benefit of tamoxifen and aromatase inhibitor in male and female breast cancer.
    Eggemann H; Altmann U; Costa SD; Ignatov A
    J Cancer Res Clin Oncol; 2018 Feb; 144(2):337-341. PubMed ID: 29098396
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment Restarting After Discontinuation of Adjuvant Hormone Therapy in Breast Cancer Patients.
    He W; Smedby KE; Fang F; Olsson H; Margolin S; Hall P; Czene K
    J Natl Cancer Inst; 2017 Oct; 109(10):. PubMed ID: 28423398
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.
    Jakesz R; Greil R; Gnant M; Schmid M; Kwasny W; Kubista E; Mlineritsch B; Tausch C; Stierer M; Hofbauer F; Renner K; Dadak C; Rücklinger E; Samonigg H;
    J Natl Cancer Inst; 2007 Dec; 99(24):1845-53. PubMed ID: 18073378
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Time on treatment of everolimus and chemotherapy among postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative metastatic breast cancer: a retrospective claims study in the US.
    Li N; Hao Y; Kageleiry A; Peeples M; Fang A; Koo V; Wu EQ; Guérin A
    Curr Med Res Opin; 2016; 32(2):385-94. PubMed ID: 26651842
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016.
    Deluche E; Antoine A; Bachelot T; Lardy-Cleaud A; Dieras V; Brain E; Debled M; Jacot W; Mouret-Reynier MA; Goncalves A; Dalenc F; Patsouris A; Ferrero JM; Levy C; Lorgis V; Vanlemmens L; Lefeuvre-Plesse C; Mathoulin-Pelissier S; Petit T; Uwer L; Jouannaud C; Leheurteur M; Lacroix-Triki M; Courtinard C; Perol D; Robain M; Delaloge S
    Eur J Cancer; 2020 Apr; 129():60-70. PubMed ID: 32135312
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: a national population-based observational study (2006-2014).
    Daniels B; Kiely BE; Houssami N; Lord SJ; Dobbins T; Lu CY; Ward RL; Pearson SA
    Br J Cancer; 2018 Feb; 118(3):441-447. PubMed ID: 29136405
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
    Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
    J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
    [TBL] [Abstract][Full Text] [Related]  

  • 58. De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry.
    Tripathy D; Brufsky A; Cobleigh M; Jahanzeb M; Kaufman PA; Mason G; O'Shaughnessy J; Rugo HS; Swain SM; Yardley DA; Chu L; Li H; Antao V; Hurvitz SA
    Oncologist; 2020 Feb; 25(2):e214-e222. PubMed ID: 32043771
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Predictive factors on outcomes in metaplastic breast cancer.
    Leyrer CM; Berriochoa CA; Agrawal S; Donaldson A; Calhoun BC; Shah C; Stewart R; Moore HCF; Tendulkar RD
    Breast Cancer Res Treat; 2017 Oct; 165(3):499-504. PubMed ID: 28689362
    [TBL] [Abstract][Full Text] [Related]  

  • 60. MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer.
    Gogas H; Kotoula V; Alexopoulou Z; Christodoulou C; Kostopoulos I; Bobos M; Raptou G; Charalambous E; Tsolaki E; Xanthakis I; Pentheroudakis G; Koutras A; Bafaloukos D; Papakostas P; Aravantinos G; Psyrri A; Petraki K; Kalogeras KT; Pectasides D; Fountzilas G
    J Transl Med; 2016 May; 14(1):136. PubMed ID: 27184134
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.